Cytosorbents (NASDAQ:CTSO - Get Free Report) is expected to be releasing its earnings data after the market closes on Thursday, March 6th. Analysts expect Cytosorbents to post earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.
Cytosorbents Stock Performance
Shares of Cytosorbents stock traded down $0.01 during trading on Friday, reaching $1.06. The company's stock had a trading volume of 81,334 shares, compared to its average volume of 330,319. The company has a 50-day moving average price of $1.03 and a two-hundred day moving average price of $1.04. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The firm has a market cap of $57.96 million, a PE ratio of -2.94 and a beta of 0.61.
Wall Street Analysts Forecast Growth
Several analysts have commented on the company. StockNews.com began coverage on Cytosorbents in a research note on Sunday. They set a "hold" rating for the company. HC Wainwright restated a "neutral" rating and set a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Finally, D. Boral Capital restated a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $4.67.
Read Our Latest Research Report on Cytosorbents
About Cytosorbents
(
Get Free Report)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Featured Stories
Before you consider Cytosorbents, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.
While Cytosorbents currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
